Liquidia (LQDA) closed at $38.86 on October 21, 2026, up 6.9% from the previous close, on volume of 3,561,418 shares (30-day average 4,933,602).
Data as of October 21, 2026.
Newsfile (Wed, 21-Oct 10:01 AM ET)
Business Wire (Tue, 13-Oct 6:18 PM ET)
Globe Newswire (Tue, 13-Oct 5:44 PM ET)
Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky
PRNewswire (Mon, 12-Oct 2:55 PM ET)
Globe Newswire (Thu, 8-Oct 10:18 AM ET)
Business Wire (Wed, 7-Oct 10:50 PM ET)
Globe Newswire (Wed, 7-Oct 4:56 PM ET)
ACCESS Newswire (Wed, 7-Oct 10:30 AM ET)
Globe Newswire (Tue, 6-Oct 3:36 PM ET)
PRNewswire (Tue, 6-Oct 2:39 PM ET)
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Liquidia trades on the NASDAQ stock market under the symbol LQDA.
As of October 21, 2026, LQDA stock price climbed to $38.86 with 3,561,418 million shares trading.
LQDA has a beta of 0.56, meaning it tends to be less sensitive to market movements. LQDA has a correlation of 0.00 to the broad based SPY ETF.
LQDA has a market cap of $3.45 billion. This is considered a Mid Cap stock.
Last quarter Liquidia reported $172 million in Revenue and $.74 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.07.
In the last 3 years, LQDA traded as high as $93.61 and as low as $6.04.
The top ETF exchange traded funds that LQDA belongs to (by Net Assets): IJR, VTI, IWM, XSMO, VXF.
LQDA has outperformed the market in the last year with a price return of +59.0% while the SPY ETF gained +16.3%. However, in the short term, LQDA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -49.6% vs +4.4% return in SPY. But in the last 2 weeks, LQDA shares have fared better than the market returning +50.0% compared to SPY -0.8%.
LQDA support price is $33.97 and resistance is $38.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LQDA shares will trade within this expected range on the day.
